Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer

Gemcitabine Plus Erlotinib for Advanced Pancreatic Cancer: A Systematic Review with Meta-Analysis

(2013) Zu-Yao Yang et al.   PLoS One

Targeting EGFR in Pancreatic Cancer Treatment

(2012) T. Troiani et al.   CURRENT DRUG TARGETS

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer

(2010) Kentaro Sudo et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer

(2009) C Yoo et al.   BRITISH JOURNAL OF CANCER

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

(2008) David Cameron et al.   BREAST CANCER RESEARCH AND TREATMENT